Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma

BACKGROUND: A phase II trial of pasireotide was performed to assess its efficacy and safety in advanced or metastatic hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Patients with advanced HCC and Child–Pugh score ≤7 received pasireotide LAR 60 mg intramuscularly every 28 days. Primary endpoin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Hepatocell Carcinoma
Hlavní autoři: Feun, Lynn G, Wangpaichitr, Medhi, Li, Ying-Ying, Kwon, Deukwoo, Richman, Stephen P, Hosein, Peter J, Savaraj, Niramol
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2018
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5769585/
https://ncbi.nlm.nih.gov/pubmed/29392123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S153672
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky